Coats Group (LSE:COA), the London-listed industrial thread and footwear components business, is trying to grow faster than the markets it serves at a time when those markets are shrinking. Its answer has been to reshape itself around two divisions, Apparel and Footwear, and to buy OrthoLite, a maker of insoles and foams, to deepen its position in shoes.

The latest evidence came in interim results published on 28 July 2026. For the six months to 30 June 2026, Coats reported Revenue of $837m, up 19% on a reported basis largely because of the OrthoLite acquisition, and up 1% organically. The company said that growth came while its end markets declined by a mid-single-digit percentage, which is the core of its pitch: outperformance through share gains, new products and adjacencies rather than a cyclical recovery.

Adjusted operating profit (EBIT) was $166m, with the Margin held at 19.8%. Management kept full-year expectations unchanged. The shares rose almost 8% on results day.

From Thread Supplier to Footwear Platform

Coats is best known as the world's largest supplier of industrial thread, selling to garment and footwear manufacturers. It earns money by supplying high-volume inputs that brands specify for quality and consistency, and has added adjacent products such as composite tapes and software.

In the second half of 2025 the group simplified its reporting. The former Performance Materials division was split up: roughly 80% of it, covering Personal Protection and Industrials, now sits within Apparel, while the remaining Telecom and Energy business, around 20%, sits within Footwear alongside OrthoLite. It had already exited its Americas Yarns Business in June 2025.

The biggest move was OrthoLite. Coats agreed the deal in July 2025 at an Enterprise value of $770m, funded partly through a Capital raise, and completed it in October 2025. The stated aim was to create a leading Tier 2 supplier of critical footwear components.

What the First-Half Numbers Show

The interim figures split as follows:

  • Apparel revenue of $486m, up 1% organically, with adjusted EBIT of $92m and an 18.9% margin. Coats pointed to strong outperformance in the Chinese domestic market and in automotive thread.
  • Footwear revenue of $351m, flat organically but up 57% on a reported basis including OrthoLite, with adjusted EBIT of $74m and a 21.1% margin, up 30 basis points.

A trading statement on 20 May covering January to April had shown Footwear down 4% organically as customers kept inventories low, but Coats said the division accelerated significantly in the second quarter, helped by easier comparisons after the US Tariff announcements of April 2025.

OrthoLite's revenue was lower year on year, which the company put down to temporary capacity constraints in Indonesia, where it is expanding. Adjusted Earnings Per Share were 4.4 cents, held back by higher interest costs from the acquisition. Free Cash Flow in the half was $30m, net Debt stood at $842m and Leverage was 2.3 times. The Interim Dividend was raised by 5% to 1.05 cents.

The Growth Levers Management Is Pulling

Chief executive David Paja's case rests on several levers. The first is OrthoLite synergies. Coats expects about $5m of cost synergies in 2026, rising to at least $20m by 2028, and has identified what it describes as more than $40m of annual incremental revenue by 2030 from sales synergies. New areas include Cirql sustainable midsoles, safety insoles and supercritical foam, with first launches expected in the second half of 2026.

The second lever is newer product lines. Composite energy tapes generated $9m of sales in the first half, against $11m for the whole of 2025. Sales of 100% recycled thread rose 11% to $297m, while bookings at Coats Digital, its software arm, rose 57% following the launch of GSD Quest, an AI costing tool.

The third lever is cost. Coats expects incremental cost actions to deliver around $15m of benefits in the second half. Chief financial officer Hannah Nicholls said the second-half EBIT improvement "does not require anything heroic", pointing to pricing already secured as well as cost savings.

Targets, Cash and the Dividend

In its 2025 results, published on 5 March 2026, Coats reported revenue of $1,465m, adjusted EBIT of $290m, a margin of 19.8%, and record free cash flow of $160m. The full-year dividend was 3.28 cents, up 5%.

At the same time it upgraded medium-term targets. It now aims for average revenue growth above 5% through the cycle, an Operating Margin of 21% to 23% (previously 19% to 21%), cumulative free cash flow of about $1bn over five years (previously $750m) and annual growth in earnings per share of more than 10%. These are company ambitions, not forecasts.

Capital allocation is focused on paying down debt for now. Coats has said it will consider share Buybacks or disciplined acquisitions only after leverage falls to 2 times net debt to EBITDA. It had earlier guided to leverage below 2 times by the end of 2026.

The Risks That Could Unravel the Plan

The main risk is the market. Management said on the results call that apparel and footwear volumes remain roughly 10% below 2019 levels, and brands have been destocking for a long time. Guidance for the rest of the year assumes modest market declines in the second half; a sharper downturn, or a fresh round of tariff uncertainty, would test that assumption.

Execution is another. OrthoLite's Indonesian capacity problems have already held back sales, and the revenue synergies are ambitious and largely unproven. Coats also said the conflict in the Middle East has caused cost Volatility since February 2026, which it has countered with pricing and operational measures. Finally, higher debt means earnings are more sensitive to interest costs than before the deal.

What to Watch Next

The next scheduled milestone is a trading update, which Coats last issued in early November in 2025. Key signals will be whether Footwear's second-quarter pick-up has continued, progress on OrthoLite's Indonesian capacity and new launches, and whether leverage is heading towards the 2 times level that would open the door to buybacks. The board is also changing hands: Tim Cobbold, chair of Spirax Group, became chair on 1 August 2026, succeeding David Gosnell.

The Bottom Line

Coats is growing modestly in weak markets, and it has held margins steady while taking on a large acquisition. The OrthoLite deal gives it a broader role in footwear. Against that, volumes remain below pre-pandemic levels, the synergy targets have yet to be proven, and debt is higher. The second half of 2026 will show whether management's plan for faster growth is working.